Abstract
Context: Anti-Mü llerian hormone (AMH)-based age at menopause predictions remain cumbersome due to predictive inaccuracy. Objective: To perform an individual patient data meta-Analysis, regarding AMH-based menopause prediction. Design: A systematic literature search was performed using PubMed, Embase, and Cochrane databases. Prospective cohort studies regarding menopause prediction using serum AMH levels were selected by consensus discussion. Individual cases were included if experiencing a regular cycle at baseline. Exclusion criteria were hormone use and gynecological surgery. Results: This meta-Analysis included 2596women, and 1077 experiencedmenopause. A multivariable Cox regression analysis assessed time to menopause using age and AMH. AMH predicted time to menopause; however, added value on top of age was poor [age alone: C-statistic, 84%; age + AMH: hazard ratio (HR), 0.66; 95% CI, 0.61 to 0.71; C-statistic, 86%). Moreover, the capacity of AMH to predict early (#45 years) and late menopause (55 years) was assessed. An added effect of AMH was demonstrated for early menopause (age alone: C-statistic 52%; age + AMH: HR, 0.33; 95%, CI 0.24 to 0.45; C-statistic, 80%). A Weibull regression model calculating individual age at menopause revealed that predictive inaccuracy remained present and increased with decreasing age atmenopause. Lastly, a check of nonproportionality of the predictive effect ofAMHdemonstrated a reduced predictive effect with increasing age. onclusion: AMH was a significant predictor of time to menopause and especially of time to early menopause. However, individual predictions of age at menopause demonstrated a limited precision, particularly when concerning early age atmenopause, making clinical application troublesome.
| Original language | English |
|---|---|
| Pages (from-to) | 3593-3600 |
| Number of pages | 8 |
| Journal | Journal of Clinical Endocrinology and Metabolism |
| Volume | 103 |
| Issue number | 10 |
| Early online date | 18 Jul 2018 |
| DOIs | |
| Publication status | Published - 1 Oct 2018 |
Funding
Disclosure Summary: F.J.M.B. is a member of the external advisory board for Ferring BV, a member of the external advisory board for Merck Serono, and a consultant for Gedeon Richter and is involved in educational activities for Ferring BV, strategic cooperationwithRocheonautomatedAMHassaydevelopment, and research cooperation with Ansh Laboratories. B.W.M. reports consultancy for ObsEva, Merck Serono, and Guerbet and is supported by National Health and Medical Research Council Practitioner Fellowship GNT1082548. The remaining authors have nothing to disclose.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Does AMH relate to timing of menopause? results of an individual patient data meta-analysis'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS